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Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: To identify predictors for high treatment costs in
individuals diagnosed with Generalized Anxiety Disorder (GAD)
with or without pain. METHODS: This analysis was conducted
using the PharMetrics Integrated Outcomes Database. Indivi-
duals aged 18–64 diagnosed with GAD (ICD9-CM: 30002)
between 1/2003 and 6/2004 who had continuous eligibility 6-
month prior and 1-year following GAD diagnosis were identi-
ﬁed. Annual treatment costs during the year after GAD diagnosis
were examined. The highest spenders (top 10%) of patients were
compared with the rest on demographics, medication use and
costs. Logistic regressions were used to identify predictors for
high treatment costs. Patients with pain or without pain were
examined separately. RESULTS: A total of 36,435 patients (67%
female, mean age 41.5 years) were included in this analysis. The
mean treatment costs were $49,248 for the top 10% spenders
and $3836 for the rest. The top10% spenders accounted for
58.8% of the total costs. Patients with pain (N = 22,133) were
associated with higher costs than those without pain (N =
14,302) ($11,445 vs. $3630, p < 0.001). Logistic regressions
revealed signiﬁcant risk factors for high costs including diagnoses
of schizophrenia (odds ratio (OR) = 2.03, p < 0.001), diabetes
(OR = 1.61, p < 0.001), asthma (OR = 1.55, p < 0.001), neuro-
pain (OR = 1.48, p < 0.001), musculoskeletal pain (OR = 1.46,
p < 0.001), depression (OR = 1.31, p < 0.001), and alcohol abuse
(OR = 1.66, p < 0.001); prior utilization of narcotics (OR = 1.62,
p < 0.001), emergence services (OR = 1.57, p < 0.001), hospi-
talizations (OR = 1.60, p < 0.001). Similar predictors were
obtained for GAD with pain but fewer predictors for GAD
without pain. CONCLUSION: This analysis showed that the top
10% spenders of GAD patients consumed nearly 60% of the
total costs. GAD patients with pain incurred nearly 3 times as
much cost as GAD patients without pain. The presence of prior
pain, depression, other comorbidities, and prior resource uti-
lization were signiﬁcant predictors for high treatment costs.
Special attention should be paid to those high costly patients in
management of GAD.
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OBJECTIVES: To assess the impact of comorbid depression and
pain on treatment costs for individuals diagnosed with General-
ized Anxiety Disorder (GAD). METHODS: Using the PharMet-
rics Integrated Outcomes Database, individuals were included in
the study if they were: diagnosed with GAD (ICD9-CM: 30002)
between 1/2003 and 6/2004 (the diagnosis date as the index
date); no diagnosis of GAD 6-month prior the index date; con-
tinuously eligible for insurance coverage for 6-month prior and
12-month post the index date; and 18–64 years old. Total and
component treatment costs during the year following GAD diag-
nosis were compared among four patient groups: GAD only;
GAD/depression; GAD/pain; and GAD/depression/pain. General
Linear Models (GLM) controlling patient demographics (age,
gender, region and type of insurance plan), clinical characteris-
tics (provider specialty and other comorbidities), and prior costs
were used to evaluate the marginal impact of comorbid depres-
sion and/or pain on treatment costs. RESULTS: Of 36,435
patients (mean age 41.5 years; 67% female) included in this
study, 23.8% were GAD only, 15.5% GAD/depression, 32.8%
GAD/pain, and 28.0% GAD/depression/pain. The average total
annual treatment costs were $8377 for all patients. Results from
GLM regressions showed that compared to patients with GAD
only, total treatment costs were $837 higher for GAD patients
with depression (p < 0.001), $3429 higher for GAD patients with
pain (p < 0.001), and $7503 higher for those with both depres-
sion and pain (p < 0.001). Similar results were also found for
component costs including inpatient and outpatient costs. CON-
CLUSION: This study demonstrated that the majority of GAD
patients also suffered from depression or pain and a large portion
had both depression and pain. Comorbid depression and pain
had signiﬁcant impact on treatment costs, especially those with
pain or with both depression and pain. This suggested that an
optimal treatment strategy of GAD needs to take comorbid
depression and pain into consideration.
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OBJECTIVES: This study determined incremental Medicaid
expenditures associated with dementia among Indiana 
Medicaid recipients in 2004. METHODS: Analysis of Indiana
Medicaid claims and enrollment ﬁles was conducted. Sample
inclusion criteria were being at least 40 years old and having
Indiana Medicaid eligibility in 2004. Twenty-six ICD-9 diagno-
sis codes determined in a prior study to be speciﬁc for dementia
were used to identify dementia. Regression models were devel-
oped to estimate incremental expenditures in U.S. dollars.
Assessment of model ﬁt was used to select from OLS regression,
OLS on log of response variables, generalized linear negative
binominal, and zero-inﬂated negative binomial models. Based on
ﬁt and Voung statistics, zero-inﬂated negative binomial regres-
sion was used to ﬁt separate models for total expenditures and
expenditure subcategories. Models included covariates for age,
gender, race, marital status, geographic region, months of Med-
icaid eligibility, months of spend-down in effect, months of
Medicare coverage, mortality, and Charlson comorbidity index
score. RESULTS: A total of 145,684 individuals meeting inclu-
sion criteria were identiﬁed, 18,950 (13%) had dementia. Indi-
viduals with dementia had more comorbidity, were older, and
were more likely to be female, white, unmarried, and to die
during the study period. After adjusting for covariates, Indiana
Medicaid spent, mean (standard error), $9829 (211) p < 0.001,
more per recipient with dementia in incremental expenditures
associated with the disease. Much of the incremental expendi-
tures were due to nursing home expenditures $9154 (141) p <
0.001. Drug expenditures accounted for the second largest com-
ponent of the incremental expenditures $970 (37) p < 0.001, fol-
lowed by inpatient expenditures $211 (23) p < 0.001 and other
medical expenditures $128 (57) p < 0.05. Dementia was associ-
ated with lower outpatient expenditures $−78 (2.50) p < 0.001.
CONCLUSION: Incremental Medicaid expenditures associated
with dementia were substantial even after adjusting for other risk
